Recent Company News

• 07:01 AM ET Oct 15, 2026
  

  Immunocore announces first patient dosed in Phase 1 trial of IMC-S118AI tissue-specific autoimmune candidate for patients with type 1 diabetes ($28.34, 0.00)

• 10:01 AM ET Oct 14, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (256 total)

• 11:34 AM ET Oct 06, 2026
  

  StreetAccount Summary - US unusual volume traders

• 03:17 PM ET Sep 14, 2026
  

  Transcript Intelligence: Immunocore Holdings at Morgan Stanley Global Healthcare Conference ($32.81, +0.21)

• 07:02 AM ET Sep 14, 2026
  

  Immunocore achieves target enrollment (540 patients) in registrational TEBE-AM trial with KIMMTRAK (tebentafusp) in previously treated advanced melanoma ($32.60, 0.00)

• 03:25 PM ET Sep 10, 2026
  

  Transcript Intelligence: Immunocore Holdings at Cantor Global Healthcare Conference ($33.21, -1.26)

• 11:37 PM ET Aug 23, 2026
  

  TD Cowen assumes/transfers AGIO, ATRA, CABA, others

• 08:52 AM ET Aug 21, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:52 AM ET Aug 21, 2026
  

  JPMorgan reinstates AMRN, EBS, IMCR, others

• 07:39 PM ET Aug 06, 2026
  

  Transcript Intelligence: Immunocore Holdings Q2 Earnings Guidance ($34.50, +1.21)